We are live on ! Find out more
CEROW

CERo Therapeutics Warrants
CEROW

Delisted

CEROW was delisted on the 30th of October, 2025.

Back to rankings

37 hedge funds and large institutions have $425K invested in CERo Therapeutics Warrants in 2024 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 4 increasing their positions, 9 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

124% more capital invested

Capital invested by funds: $190K → $425K (+$235K)

8% less funds holding

Funds holding: 40 → 37 (-3)

25% less first-time investments, than exits

New positions opened: 6 | Existing positions closed: 8

56% less repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 9

Holders
37
Holders Change
-3
Holders Change %
-7.5%
% of All Funds
0.53%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
4
Reduced
9
Closed
8
Calls
$7K
Puts
–
Net Calls
+$7K
Net Calls Change
+$4K

Top Buyers

Rank Fund Capital Flow
1
CAC
Cowen and Company
New York
+$26.7K
2
ACM
Atalaya Capital Management
New York
+$12.2K
3
ICM
Ionic Capital Management
New York
+$4.88K
4
CF
Cantor Fitzgerald
New York
+$4.71K
5
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$848

Top Sellers

Rank Fund Capital Flow
1
SCM
Segantii Capital Management
Hong Kong
-$55K
2
PC
Periscope Capital
Ontario, Canada
-$22.2K
3
PAMP
Polar Asset Management Partners
Ontario, Canada
-$8.25K
4
AA
AQR Arbitrage
Connecticut
-$5.8K
5
CCM
Context Capital Management
California
-$4.74K
Name Holding Trade Value Shares
Change 		Change in
Stake
SSA
26
Schonfeld Strategic Advisors
New York
$1.36K -$813 -13,373 -40%
Susquehanna International Group
27
Susquehanna International Group
Pennsylvania
$1.24K +$848 +13,945 New
Calamos Advisors
28
Calamos Advisors
Illinois
$1.11K – – –
DCM
29
Dupont Capital Management
Delaware
$1.11K – – –
FTUS
30
Flow Traders U.S.
New York
$1K -$593 -9,753 -35%
Walleye Trading
31
Walleye Trading
New York
$919 – – –
SRF
32
Silver Rock Financial
California
$834 – – –
CSS
33
Cubist Systematic Strategies
Connecticut
$716 -$379 -6,240 -37%
EAM
34
Exos Asset Management
New York
$252 +$225 +3,700 New
AA
35
Ancora Advisors
Ohio
$170 – – –
Bank of America
36
Bank of America
North Carolina
$14 – – –
PA
37
Pineridge Advisors
Missouri
$10 +$9 +150 New
TRCT
38
Tower Research Capital (TRC)
New York
$6 +$5 +87 New
PAMP
39
Polar Asset Management Partners
Ontario, Canada
– -$8.25K -300,000 Closed
AA
40
AQR Arbitrage
Connecticut
– -$5.8K -246,696 Closed
RCM
41
Radcliffe Capital Management
Pennsylvania
– -$4.11K -149,380 Closed
CH
42
CVI Holdings
Delaware
– -$1.03K -43,673 Closed
SFM
43
Spartan Fund Management
Canada
– -$688 -25,000 Closed
Parallax Volatility Advisers
44
Parallax Volatility Advisers
California
– -$399 -14,502 Closed
SCM
45
Segantii Capital Management
Hong Kong
– -$55K -5,000 Closed
RCM
46
Robinson Capital Management
Michigan
– -$24 -1,000 Closed
1
2

CEROW Hedge Fund Activity: Q1 2024 in Review

37 of the 6,943 institutional investors tracked by Wall St. Rank reported a position in CERo Therapeutics Warrants (CEROW) for Q1 2024, worth a combined $425K — up 124% from $190K a quarter earlier.

Sellers outnumbered buyers: 8 funds closed out of CEROW and 6 opened new positions — a net loss of 2 holders — while 9 trimmed existing stakes and 4 added.

The largest buyer was Cowen and Company, adding an estimated $26.7K. The largest seller was Segantii Capital Management, exiting entirely with an estimated $55K sold.

  • 37 institutional investors held CERo Therapeutics Warrants (CEROW) as of Q1 2024, down from 40 in Q4 2023.
  • Funds reported $425K of CERo Therapeutics Warrants stock for Q1 2024, up 124% quarter-over-quarter.
  • 6 funds opened new CERo Therapeutics Warrants positions in Q1 2024 and 8 closed out, a net change of -2 holders.
  • The largest CERo Therapeutics Warrants buyer in Q1 2024 was Cowen and Company, an estimated $26.7K added.
  • The largest CERo Therapeutics Warrants seller in Q1 2024 was Segantii Capital Management, an estimated $55K sold.

Based on aggregated 13F filings for Q1 2024.